Agendia names Mark R. Straley as new CEO
Mr. Straley brings more than 25 years of international experience developing and commercializing clinical diagnostics and laboratory services. Most recently he served as President, Anatomical Pathology of Thermo Fisher Scientific (Waltham, Mass.).
Prior to this position he was President and CEO of Metamark Genetics (Cambridge, Mass.), a biotech company focusing on the development of prognostic and predictive diagnostic tests for personalized treatment of cancer patients. ■